Nyxoah Sa ( (NYXH) ) has released its Q2 earnings. Here is a breakdown of the information Nyxoah Sa presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Nyxoah SA is a medical technology company specializing in innovative solutions for treating Obstructive Sleep Apnea (OSA) through neuromodulation, with its flagship product being the Genio system, a unique bilateral hypoglossal neurostimulation therapy.
In its latest earnings report, Nyxoah announced significant milestones, including the U.S. FDA’s approval of its Genio system, marking its entry into the U.S. market. The company has commenced the commercial launch of this system, which is the first of its kind approved in the United States.
Financially, Nyxoah reported a revenue of €1.3 million for the second quarter of 2025, reflecting a 74% increase from the same period last year. Despite this growth, the company faced an operating loss of €19.9 million, driven by increased expenses related to research and development and the commercialization of the Genio system. The company’s cash position stood at €43.0 million as of June 30, 2025.
Nyxoah’s strategic focus on the U.S. market, supported by the FDA approval, positions it for potential growth in addressing the needs of OSA patients. The management remains optimistic about the transformative impact of the Genio system and is committed to executing its commercial strategy effectively.